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Abstract
Background. Leptomeningeal disease and hydrocephalus are present in up to 30% of patients with diffuse intrinsic
pontine glioma (DIPG), however there are no animal models of cerebrospinal fluid (CSF) dissemination. As the
tumor–CSF–ependymal microenvironment may play an important role in tumor pathogenesis, we identified characteristics of the Nestin-tumor virus A (Nestin-Tva) genetically engineered mouse model that make it ideal to study
the interaction of tumor cells with the CSF and its associated pathways with implications for the development of
treatment approaches to address CSF dissemination in DIPG.
Methods. A Nestin-Tva model of DIPG utilizing the 3 most common DIPG genetic alterations (H3.3K27M, PDGF-B,
and p53) was used for this study. All mice underwent MR imaging and a subset underwent histopathologic analysis
with H&E and immunostaining.
Results. Tumor dissemination within the CSF pathways (ventricles, leptomeninges) from the subependyma was present in
76% (25/33) of mice, with invasion of the choroid plexus, disruption of the ciliated ependyma and regional subependymal
fluid accumulation. Ventricular enlargement consistent with hydrocephalus was present in 94% (31/33). Ventricle volume correlated with region-specific transependymal CSF flow (periventricularT2 signal), localized anterior to the lateral ventricles.
Conclusions. This is the first study to report CSF pathway tumor dissemination associated with subependymal
tumor in an animal model of DIPG and is representative of CSF dissemination seen clinically. Understanding the
CSF–tumor–ependymal microenvironment has significant implications for treatment of DIPG through targeting
mechanisms of tumor spread within the CSF pathways.

Key Points
• CSF pathway tumor dissemination is observed in DIPG Nestin-Tva GEMMs.
• We observe ependymal and subependymal damage and localized transependymal CSF flow.
• This model offers a new avenue for study of tumor–CSF–ependymal interaction in DIPG.
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Importance of the Study

The spread of tumor cells to distant areas of the brain,
spine, or meninges is seen in about 20% of DIPG patients,1–3 yet there are no published reports on the study of
cerebrospinal fluid (CSF) dissemination of tumor, associated hydrocephalus or ependymal injury. Although there
have been limited studies of DIPG dissemination through
the CSF pathways, recent histopathologic and genetic examination of brain autopsy specimens has revealed extensive intracranial dissemination in DIPG cases,1,4 and
a seminal study of over 1000 international DIPG patients
revealed extrapontine extension of the tumor in 92% of
short-term survivors and 86% long-term survivors (survival ≥2 years).5 Given the aggressiveness of DIPG and
lack of curative treatments, it is necessary to understand
tumor spread within the CSF pathways.
Approximately 35% of children with DIPG develop hydrocephalus at an average of 5 months after diagnosis.6
This may result from tumor dissemination within the
CSF pathways as not all cases of hydrocephalus are from
intraventricular obstruction.7 Potential mechanisms underlying the development of hydrocephalus including interaction of tumor cells with the CSF and associated pathways
(leptomeninges, ventricular ependyma) have not yet been
studied,8 and as a consequence, the origins and development of DIPG tumor spread and associated hydrocephalus
are not clear. DIPGs have been found to spread to the stem
cell niche of the subventricular zone (SVZ) of the lateral
ventricles in humans,6 and previous studies have shown
predilection for glioma spread to the SVZ.9 These tumor–
SVZ interactions within the CSF–tumor–ependyma microenvironment represent an avenue for tumor spread that
has not yet been studied in animal models of DIPG.
Over the past several decades, preclinical animal
models of glioma have been widely developed and used
to study the development and treatment of DIPG tumors.
Misuraca et al. described the advantages of genetically
engineered mouse models (GEMMs) in providing the opportunity to study tumors that arise in their natural microenvironment in immune-proficient mice.10 Over time,
GEMMs using the replication-competent avian sarcomaleucosis virus long-terminal repeat with splice acceptor/
tumor virus A (RCAS/Tva) system have evolved to closely
parallel the clinical disease, allowing detailed study of

tumor. However, as there are currently no curative treatments for DIPG, it is important to
consider the cerebrospinal fluid (CSF)–tumor–
ependymal microenvironment as a mechanism
for tumor pathogenesis. This study is the first
to report widespread CSF pathway disease in
a DIPG animal model with associated hydrocephalus, ependymal injury, and ependymal/
subependymal tumor infiltration. These findings have important implications for DIPG treatment approaches targeting CSF dissemination.

the biology of the disease in an in vivo setting. As a result, genetic advances and insight into new mechanisms driving DIPG tumorigenesis have been described.11
However, the prevalence of leptomeningeal disease and
associated CSF pathway pathology and extra-pontine
neuraxis disease in these mice has yet to be examined. Given the clinical rates of CSF pathway spread in
DIPG, we evaluated CSF–tumor–ependyma interactions
in a Nestin-tumor virus A (Nestin-Tva)-based GEMM of
DIPG. We report the first in-depth animal model evaluation of leptomeningeal disease, neuraxis disease,
intraventricular dissemination following subependymal
tumor infiltration, and hydrocephalus in a DIPG model
with implications for clinical pathogenesis and novel
treatment approaches.

Methods
Additional details are provided in Supplementary Material.
All animal use protocols were approved by our institution’s
Animal Care and Use Committee protocol 20180185.

Animal Model
P53flox/flox homozygous, Nestin-Tva+ GEMMs of DIPG were
used for this study. To generate the model, DF-1 chick fibroblast cells (ATCC CRL-12203) were transfected with one of
three RCAS plasmids expressing RCAS-H3.3K27M, RCASPDGFB, and RCAS-Cre with FuGENE 6 Transfection Reagent
(#E2311, Promega, Madison, WI) to generate the three most
highly occurring DIPG genetic alterations (H3.3K27M mutation, PDGFB overexpression, p53 loss).10 Once confluent,
cells were harvested in a 1:1:1 H3.3K27M:PDGFB:Cre ratio
in a 30 µl medium and injected intracranially into postnatal
day 7 mice at 3 mm deep of lambda.
Three cohorts of mice were created. The first received
a 100 000 DF-1 cell injection into the pons. The second
received a 50 000 DF-1 cell injection into the lateral ventricles, and the third received a 50 000 DF-1 cell injection
into the pons.
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Preclinical models of diffuse intrinsic pontine
glioma (DIPG) have been widely developed for
use in researching the initiation, progression,
and treatment of DIPG. Early transplantationbased models used stereotactic implantation of
glioma cells into the rodent brain, which were
followed by the development of human xenograft models, and later genetically engineered
models. The development of these models
has largely focused on focal location of tumor
in the brainstem and the genetic origin of the
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Histology
Following the MRI imaging, mice were anesthetized, and
a cohort of mouse brains containing tumor were collected
(Supplementary Material). Formalin-fixed paraffin embedded sections were stained with H&E to assess tumor
extent and examine the ependymal and subependymal
wall, and immunohistochemistry for beta-IV tubulin to
assess ependymal cilia. 1:200 dilution Olig2 (ab109186,
Abcam) and 1:100 dilution Ki67 (ab16667, Abcam) were
used to confirm high-grade glioma (HGG) characteristics of
the tumor, and 1:400 dilution GFAP (ab7260, Abcam), 1:100
dilution CD45 (ab10558, Abcam), 1:200 dilution CD163
(ab182422, Abcam), and 1:500 dilution CD8 (ab209775,
Abcam) were used to examine the immune composition.

Human Specimens
We obtained sections from the pons and fourth ventricle of
a human DIPG specimen (age 12 with postmortem interval
0 h. Sections were stained with H&E to assess tumor extent
and ependymal wall integrity. (CMC43450040, Cell Marque,
CA, USA), (760-2505, Ventana, AZ, USA), (CMC16321040, Cell
Marque, CA, USA), and (790-4460, Ventana, AZ, USA) were
used to evaluate the immune composition of tumors.

Statistical Analysis
All analyses were performed using Microsoft Office
Excel (Version 16.36) and Prism (Version 9.3.1 (350)).
Associations between continuous variables were assessed
using linear regression analysis; DIPG tumor volume was
compared to ventricle volume and total periventricular
T2 signal volume in separate tests, and ventricle volume
was compared to total periventricular T2 signal volume. All
tests were 2-tailed, and P values of less than .05 were considered statistically significant.

Results
Tumor in CSF Pathways
When 100 000 DF-1 cells were injected into the brainstem
(Figure 1, Supplementary Figure 1) basophilic, mitotic

Ependymal Damage and Tumor in the
Subependymal and Subventricular Zones
Mechanical disruption of the ependyma was present in
all seven mice with histopathologic analysis from the
100 000 DF-1 cell pontine injection cohort. On H&E, regions of subependymal tumor were characterized by
pseudopalisading necrosis, increased mitotic activity,
and areas of hemorrhage. Tumor cells were present
from the superior SVZ to the subependymal zone in
43% (3/7) mice (Figure 4A–D), and resulted in separation of the ependyma from the underlying parenchyma
(Figures 3A, D and 4B–D). The precise neuroanatomical
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Mice were closely monitored for 3–4 weeks after the DF-1
cell injection, before undergoing T1-weighted post-contrast
and T2-weighted MRI in the Small-Animal Magnetic
Resonance Facility of the Mallinckrodt Institute of Radiology,
Washington University to track tumor development. A cohort of mice also underwent post-contrast T1-weighted and
T2-weighted MRI at 5 weeks post-DF-1 cell injection.
T1-weighted MRI images were manually segmented on
ITK-SNAP software for quantification of the ventricle and
tumor volumes.12 T2-weighted images were manually segmented for quantification of the periventricular T2-signal
volume.

tumor cells were observed along the subependyma and
CSF spaces (including the lateral, third and fourth ventricles, cerebral aqueduct, and leptomeninges) (Figure 2).
Of the 7 mice with H&E from the 100 000 DF-1 cell pontine injection cohort, 43% (3/7) had tumor throughout the
lateral ventricles. Tumor dissemination in the lateral ventricle space was closely associated with subependymal
tumor growth, which occurred in 71% (5/7) of the mice in
the 100 000 DF-1 cell pontine injection cohort (Table 1).
The fourth ventricle was filled with tumor cells in 57%
(4/7) (Figure 2B and D), while the third ventricle was filled
with tumor cells in 43% (3/7) (Figure 2C and E). Tumor
cells were present in the cerebral aqueduct in 100%
(7/7) mice, and 57% (4/7) had aqueducts that were completely obstructed by tumor cells (Supplementary Figure
2, Table 1). On MRI, 76% (25/33) were noted to have CSF
pathway tumor, indicated by contrast enhancement on
post-contrast T1-weighted MRI. Specifically, 12% (4/33)
of mice had leptomeningeal contrast enhancement,
(Supplementary Figure 3, Table 1) with additional T1
contrast-enhancing tumor in the lateral ventricles (13/33),
third ventricle (7/33), fourth ventricle (10/33), cerebral aqueduct (12/33). Tumor was also present in the thalamus
(2/33), midbrain (20/33), and cerebellum (19/33). Tumor
was present in the pons in 100% (33/33) of the mice
(Figure 2K).
To experimentally rule out CSF contamination from
the DF-1 cell injection due to technical error as a factor in
our observations of CSF pathway tumor, we performed
intraventricular injection of DF-1 cells and monitored for
tumor development. When we injected the same dose
of DF-1 cells (100 000) into the lateral ventricles as we injected into the pons, 2 litters of mice (16 total mice) died
within 1 week of injection. We subsequently lowered the
intraventricular dose to 50 000 DF-1 cells; there were no
deaths and only 33% (2/6) had tumor in any of the CSF
spaces (lateral ventricles, third ventricle, fourth ventricle,
aqueduct, leptomeninges) (Table 1, Figure 3D). To directly
compare with pontine injections, we injected 50 000 DF-1
cells into the pons. In contrast to the 50 000 DF-1 cell
intraventricular injection cohort, 83% (5/6) of the mice
had tumor in the lateral ventricle, third ventricle, fourth
ventricle, or cerebral aqueduct (Figure 3A, Table 1), while
one mouse developed leptomeningeal tumor. Overall,
there was less tumor in the ventricular system of the
intraventricular cohort compared to the intrapontine cohort 5 weeks post-DF-1 cell injection.
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RCAS plasmid

RCAS producing
DF-1 cells

Lambda
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P53 flox/flox homozygous,
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B

C

Figure 1. RCAS-based DIPG tumor model. (A) RCAS plasmids are transfected into DF-1 chick embryo cells. These cells produce RCAS viruses
and are directly injected into the brainstem of postnatal day 7 mice. (B) Three weeks after DF-1 chick fibroblast injection, mice underwent T1 postcontrast weighted (top) and T2-weighted (bottom) MRI imaging. (C) After MRI, mice were sacrificed, and brains collected. Histology using hematoxylin and eosin (H&E) shows location of tumor. Higher magnification (10×) H&E staining shows tumor growth in the brainstem characterized by
patches of basophilic staining with high mitotic activity, pseudopalisading necrosis, and hemorrhage.
  

location not be determined, as the extent of the tumor
and the accompanying hydrocephalus grossly distorted
the anatomy.
In the frontal horn of the lateral ventricles, tumor cells
formed proliferative nodules that expanded outward from
the ependyma and subependyma of the ventricle walls
into the CSF spaces. Granular ependymitis (round, inflammatory ependymal projections from the wall of the lateral
ventricle) (Figure 4E) and filamentous processes with hemorrhage (Figure 4F) were also present.
Additionally, tumor cells surrounded and invaded the
choroid plexus of the lateral and third ventricles in several

animals (Figure 4G). Cilia was present on the apical surfaces of ependymal cells in regions of undisturbed ependyma, but was only sparsely present in ependymal cells
that had underlying or invading tumor growths (Figure 4K
and L). This could also be seen in the third (Figure 4H) and
fourth (Figure 4J) ventricles.
After intraventricular injection of 50 000 DF-1 cells, there
was decreased subependymal tumor infiltration compared
to pontine injection of 50 000 DF-1 cells. Thirty-three percent (2/6) of mice with intraventricular injection had lateral ventricle subependymal tumor and 50% (3/6) had
third ventricle subependymal tumors (Table 1). In contrast,
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Figure 2. CSF Tumor dissemination in the lateral, third, and fourth ventricles and surrounding brain regions following pontine injection of DF-1
cells. (A) Representative H&E image of severe lateral ventriculomegaly and tumor cells filling the third (B) and fourth (C) ventricles 4 weeks postintrapontine injection of 100 000 DF-1 cells. Higher magnification images (D, E) show pseudopalisading necrosis and pyknotic cells. (A) 2.5× magnification, scale bar = 5 mm; (B–C) 10× magnification, scale bar = 200 um; (D) 40× magnification, scale bar = 20 um; (E) 63× magnification, scale bar = 20
um. (F) Representative image showing moderate ventriculomegaly with minimal tumor cell presence in the third (G) and fourth (H) ventricles. Higher
magnification images (I, J) show subependymal tumor infiltration in the walls of the third ventricle. (F) 2.5× magnification, scale bar = 5 mm; (G–H)
10× magnification, scale bar = 200 um; (I–J) 40× magnification, scale bar = 20 um. (K) Frequency of tumor invasion in different anatomical sites.
  

83% (5/6) of mice with intrapontine injection had lateral
ventricle subependymal tumor, and 100% (6/6) had third
ventricle subependymal tumor. Additionally, there was
a significant decrease in total subependymal tumor area
after 50 000 DF-1 cell intraventricular compared to the

50 000 DF-1 cell pontine injection cohort (Figure 3M). n = 6,
unpaired, 2-tailed t-test.
To confirm that the subependymal and intraventricular
tumor recapitulates the biology of HGG, we performed
Olig2 and Ki67 immunohistochemistry (Figure 3). In the
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Table 1. Tumor dissemination in Nestin-Tva GEMM by injection cohort and location
Injection dose and location

Proportion of
animals

Olig2
(Presence +/
absence −)

Ki67
(Presence +/
absence −)

Nestin
(Presence +/absence −)

Pons (primary) tumor

7/7

+

+

+

LV subependymal tumor

6/7

+

+

+

3V subependymal tumor

7/7

+

+

+

Intraventricular tumor

7/7

+

+

+

Leptomeningeal tumor

4/33

N/A

N/A

N/A

Pons (primary) tumor

6/6

+

+

+

LV subependymal tumor

5/6

+

+

+

3V subependymal tumor

6/6

+

+

+

Intraventricular tumor

5/6

+

+

+

Leptomeningeal tumor

1/6

N/A

N/A

N/A

100 000 DF-1 cells, pontine injection

50 000 DF-1 cells, lateral ventricle injection
Pons tumor

0/6

−

−

−

LV subependymal tumor

2/6

+

+

+

3V subependymal tumor

3/6

+

+

+

Intraventricular tumor

2/6

+

+

+

Leptomeningeal tumor

0/6

N/A

N/A

N/A

GEMM, genetically engineered mouse model.

  
50 000 DF-1 cell pontine cohort, there were no differences
in Olig2 and Ki67 positivity rate between the subependymal
and intraventriclar tumor and primary tumor (Figure 3B
and C). n = 6, 1-way ANOVA, post hoc Tukey. In contrast,
in the 50 000 DF-1 cell intraventricular cohort there were
increased Olig2 positivity rates in the ventricle tumor
compared to the subependymal tumor (Figure 3E), but
no difference in the Ki67 rate (Figure 3F). n = 6, unpaired,
2-tailed t-test. Overall, there was significantly decreased
in Olig2 and Ki67 positivity in subependymal tumor in the
intraventricular injection cohort, compared to intrapontine
(Figure 3I). n = 6, unpaired, 2-tailed t-test. There were
pseudopalisading necroses in the subependymal tumor of
the intrapontine cohort, but not the intraventricular cohort.
The subependymal tumor in the intraventricular cohort did
not appear to recapitulate the biology of HGG.

Ventriculomegaly and Hydrocephalus
Three-to-four weeks post-intrapontine DF-1 cell injection
(100 000 dose), mice displayed ventriculomegaly accompanied by doming of the skull, consistent with hydrocephalus (Supplementary Figure 4A). Total ventricle volume
ranged from 0.72 to 103.50 mm3, and hydrocephalus, defined as ventricle volumes 3 mm3 and larger, was present
in 94% (31/33) mice from the 100 000 DF-1 cell intrapontine
cohort. Tumor volume ranged from 0.136 to 16.03 mm3,
and was associated with ventricle volume (Supplementary
Figure 4D). Qualitatively, in mice with severe ventricular

enlargement, brain tissue was reduced to a ring of uneven thickness surrounding the CSF-filled ventricle with an
absence of brain tissue between the right and left lateral
ventricles in some mice. Discontinuities in the ring of brain
tissue were occasionally present, allowing communication
between the ventricles and the extra-axial spaces (Figure
5A and C).

Region-Specific Transependymal CSF Movement
In 88% (29/33) of mice from the 100 000 DF-1 cell
intrapontine cohort, the periventricular brain tissue of
the lateral ventricles was characterized by hyperintense
T2 signal consistent with periventricular fluid secondary
to transependymal CSF movement. These areas correspond with hypointense periventricular areas observed
on T1 post-contrast images (Supplementary Figure 5A and
B) and myelin pallor and edema on H&E (Supplementary
Figure 5C and D). Volume of hyperintense T2 signal ranged
from 0 to 5.231 mm3 and significantly correlated with ventricle volume (Supplementary Figure 5E). The periventricular T2 signal was localized anterior to the lateral ventricles
in 100% (29/29) of mice with periventricular T2 signal. There
was additional diffuse T2 signal posterior to the lateral
ventricles in 21% (6/29) of mice and 31% (9/29) of mice had
anterolateral signal. The mice with diffuse periventricular
T2 signal that extended into the posterior and lateral regions had larger ventricles than the mice with signal that
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Figure 3. Intraventricular injection of DF-1 cells does not recapitulate the architecture of high grade glioma. (A) Olig2, Ki67, Nestin immunostaining
of subependymal (SEZ) dissemination (left column), intraventricular (ICV) dissemination (middle column), and primary (right column) tumor regions
5 weeks post-intrapontine injection of DF-1 cells (50 000 dose). Scale bars = 50 µm. (B–C) Quantification of number of Olig2+ (B) and Ki67+ cells (C)
per 1.0 × 104 µm2 area corresponding to the conditions in (A). n = 6, One-way ANOVA, post-hoc Tukey. (D) Olig2, Ki67, Nestin immunostaining of
subependymal (left column) and intraventricular (right column) tumor regions 5 weeks post-lateral ventricle injection of DF-1 cells (50 000 dose).
Scale bars = 50 µm. (E–F) Quantification of number of Olig2+ (E) and Ki67+ cells (F) per 1.0 × 104 µm2 area corresponding to the conditions in (D).
n = 6, Unpaired, two tailed t-test. (G) Hematoxylin and eosin (H&E) histology of tumor regions 5 weeks post-intrapontine injection of DF-1 cells
(50 000 dose). Higher magnification H&E insets of regions indicated in (G) show areas of pseudopalisading necroses from the lateral ventricle
subependymal (i) and third ventricle subependymal (ii) tumor. Scale bar = 5 mm, inset scalebars = 50 µm. (H) H&E histology of tumor regions 5
weeks post-lateral ventricle injection of DF-1 cells (50 000 dose). Higher magnification H&E insets of regions indicated in (H) show tumor regions
from the lateral ventricle (i) and third ventricle (ii) subependymal tumor. Scale bar = 5 mm, inset scale bars = 50 µm. (I–J) Quantification of number
of Olig2+ cells in the subependymal (I) and intraventricular (J) tumor per 1.0 × 104 µm2 area in the intrapontine and intraventricular injection cohorts
(50 000 dose). n = 6, unpaired, two tailed t-test. (K–L) Quantification of number of Ki67+ cells in the subependymal (K) and intraventricular (L) tumor
per 1.0 × 104 µm2 area in the intrapontine and intraventricular cohorts (50 000 dose). n = 6, unpaired, two-tailed t-test. (M) Quantification of total
subependymal tumor area in the intrapontine and intraventricular injection cohorts (50 000 dose). n = 6, unpaired, two-tailed t-test. (N) Schematic
representation of lateral ventricle subependymal tumor growth into the lateral ventricle in the intrapontine injection cohorts over time. LV, lateral
ventricle; SEZ, subependymal zone.
  

was localized at the anterior regions only (Supplementary
Figure 6). n = 13, unpaired, 2-tailed t-test. Little to no signal
was observed medial to the lateral ventricles or around the
third and fourth ventricles.

Subependymal Spread in Human DIPG
Tumor cells characterized by mitoses and pyknosis could
be seen along the floor of the 4V and the underlying brain
tissue (Supplementary Figure 8). These mitoses were in

multiple locations along the subependyma of the fourth
ventricular floor and resulted in protrusion of the ependymal cells toward the ventricle (Supplementary Figure 8).
Furthermore, one of the major advantages of the GEMM
is the ability to study tumors in an intact immune system,
as DIPG tumors do not have an immunosuppressive microenvironment.13 To compare the immune composition
between the primary, subependymal, and intraventricular
tumor in the GEMM to the primary tumor in the human
condition, we performed immunostaining (Figure 5).
GEMM pontine, subependymal, and intraventricular tumor
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Figure 4. Ependymal, subependymal and choroid plexus response to tumor infiltration following pontine injection of DF-1 cells. Representative
H&E (A–J) and beta-IV Tubulin IHC (immunohistochemistry) (K–L) images 4 weeks post-intrapontine injection of 100 000 DF-1 cells. (A) Axial MRI
image and photomicrograph showing tumor in the subependyma of the lateral ventricles and within the third and fourth ventricles (red asterisks). 2.5× magnification; scale bar = 5 mm. (B–D) Photomicrograph of the subependyma of the lateral ventricle showing histologic characteristics
of high-grade glioma including pseudopalisading necrosis (black arrows) and intratumoral hemorrhage. Red asterisks indicate tumor. (B–D) 10×
magnification; scale bars = 200 µm. (E) Photomicrograph of the lateral ventricle subependyma showing granular ependymitis secondary to tumor
invasion (red arrows). 20× magnification; scale bars = 50 µm. (F) Photomicrographs showing separation of the ependyma from underlying tissue
secondary to subependymal growth of the tumor. Resulting hemorrhage is also present. 40× magnification; scale bars = 20 µm. (G) Tumor dissemination within the epithelium of the choroid plexus. Red asterisk indicates tumor around the surface of the choroid plexus. 20× magnification; scale
bars = 50 µm. (H–I) Disruption along the floor of the third ventricle secondary to hydrocephalus and tumor growth. Separation of the third ventricle
ependyma (black arrowheads) and tumor interaction with the third ventricle choroid plexus (red asterisk). (H–I) 20× magnification; scale bars = 50
µm. (J) Separation of the ependyma along the fourth ventricle floor. Black arrowheads indicate ependyma, red asterisk indicates tumor. 20× magnification; scale bars = 50 µm. (K–L) Photomicrographs showing cilia lining a section of undisturbed ependyma in the lateral ventricle (K) compared
with cilia loss in a section with overlying tumor (L). Tumor is indicated with a red asterisk. (K–L) 40× magnification; scale bars = 20 µm.
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Figure 5. Immune cell profile of GEMM and human DIPG specimen (A) CD45, GFAP, CD8, CD163 immunostaining of subependymal (SEZ) dissemination (far left column), intraventricular (ICV) dissemination (middle left column), and primary (middle right column) tumor regions in the 50 000 DF-1
cell pontine injection cohort of the DIPG Nestin-Tva genetically engineered mouse model (GEMM) and human DIPG legacy specimen (far right
column). Scale bars = 25 µm. (B–E) Number of CD45+ (B), GFAP+ (C), CD8+ (D), and CD163+ (E) cells per 0.1 mm2 area in the SEZ dissemination, ICV
dissemination, and primary tumor areas of the GEMM. Significant differences in the number of GFAP+ cells were observed in the SEZ and primary
tumor (n = 3 rodents per group, one-way ANOVA with post-hoc Tukey), however no other differences were observed.
  

areas had similar numbers of CD45+, CD8+, and CD163+
cells, and there were no differences in all staining except
for GFAP (Figure 5A, B, and D), where there was significantly increased GFAP expression in the subependymal
tumor compared to the primary tumor (Figure 5C). Due to

the limited samples that could be obtained, we could not
quantify differences between the human and GEMM primary tumors however they qualitatively appeared to have
similar numbers of CD45+, GFAP+, and CD8+ cells, while
the human primary tumor appeared to have more CD163
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Discussion
Leptomeningeal spread of tumor cells is seen in up to 30%
of human cases of DIPG.1–3,14 However, current treatment
with radiation therapy is limited to the pons, and research
on novel therapies for DIPG is largely focused on focal drug
delivery to the pons. We report the occurrence of leptomeningeal spread of tumor cells in 12% of mice in this DIPG
model. As leptomeningeal disease has not been extensively described in animal models of DIPG, this Nestin-Tva
model represents a biologically relevant system to study
DIPG and address CSF dissemination of subependymal
tumor spread through understanding the CSF–tumor–ependyma microenvironment and associated hydrocephalus.
Previously, ependymal disruption was thought to occur
through direct damage secondary to expansion of the
ventricles by hydrocephalus.15 However, through more recent understanding of ependymal biology in the setting
of DIPG, there are likely more complex interactions between tumor cells and the ependymal and subependymal
regions.16–18 In mice with the most pronounced ventricular enlargement and leptomeningeal tumor spread in
the pontine injection cohorts, tumor cell proliferation was
also present in subventricular and subependymal regions
and caused the ependyma to protrude into the ventricles.
These histological observations were similar to those in a
2014 autopsy series of 16 DIPG patients showing ventricular and subventricular disease in 10/16 of the patients.19
In this model tumor cells infiltrated other CSF contacting
surfaces, including the apical surfaces of the choroid
plexus. The tumor cells did not invade into the vascular or
connective tissue body of the choroid plexus, suggesting
the disease was localized to the epithelial cells of the
choroid plexus.
The leptomeningeal disease and damage to the ependyma and subependymal tissue may be directly associated
with disruption of the SVZ, as the tumor cells observed in
the SVZ of our mice were continuous with tumor cells in
subependymal and ependymal regions. The SVZ of the lateral ventricles is a source of neural stem cells during the
early postnatal period,20 and alterations in the SVZ may
affect the downstream function of these neuronal stem
cells with implications for the development of hydrocephalus.21–23 It has been previously suggested that pediatric
HGGs, including DIPG, seek the SVZ stem cell niche as a
sanctuary site for growth or that SVZ neuronal stem cells
harbor driver mutations and contribute to tumorigenesis.24,25 As DIPG cells are developmentally similar to cell
populations within the SVZ, there may be common trophic
signals resulting in their spread to this region.
Similar to autopsy data showing subventricular tumor
spread in the lateral and third ventricles,9,19 we observed

growth adjacent to the fourth ventricle in our patient,
indicating the potential for widespread subependymal
spread. Owing to the size of the human lateral ventricles
and pontine nature of DIPG, it was not possible to characterize the tumor interaction with the lateral and third ventricles in our patient. These observations suggest, however,
that the importance of CSF pathways and subependymal
and ependymal structures over the course of DIPG tumor
growth are conserved between humans and this mouse
model. We speculate that tumor growth and its interaction
with the ependymal and subependymal tissue, including
the SVZ, may alter the microenvironment that the ependymal cells reside in and worsen the degree of ventricular
expansion beyond the purely obstructive effects of the
DIPG tumor. An alternative hypothesis may be that hydrocephalus opens the subependymal and subventricular
zones to tumor invasion through ependymal injury, however this is unlikely to be the observed mechanism in this
GEMM as we observed tumor extension outward from the
subependymal into the ventricles.
In 2016, Misuraca et al. reported the onset of hydrocephalus in a similar model of DIPG using Pax3-Tv-a mice
following DF-1 cell injection into the cerebral cortex, however hydrocephalus has not been studied in detail in pontine DIPG mouse models.26 Hydrocephalus in our model
was defined by ventricle size >3 mm3 on MR imaging 3–4
weeks after DF-1 cell injection in the pons, however almost
all mice had an increase in ventricular size. In addition, we
found that larger tumor volume was associated with larger
ventricles. This is not surprising as the majority of mice
with hydrocephalus had evidence of an obstructive component that reflected blockage or damage in other areas
of the ventricular system along the third and fourth ventricles. Interestingly, in parallel with the small population of
5 mice with small tumors and large ventricles observed in
our study, a recent clinical study reported that the development of hydrocephalus was more likely to be associated
with smaller tumors at diagnosis.6 A potential explanation
for this inverse relationship between tumor size and hydrocephalus may be concurrent leptomeningeal disease
contributing to ventricular enlargement outside of an obstruction within the ventricular system.
Recent experimental and clinical findings reveal that in
addition to bulk,27 glymphatic,28 and lymphatic routes,29,30
CSF may flow from the ventricles throughout the parenchyma toward the subarachnoid space.31–33 This flow is
known as transependymal flow, and can be defined as the
motion of fluids and/or molecules across the ependymal
layer of cells surrounding the ventricles and into the brain
parenchyma and adjacent structures.31 Transependymal
flow or transependymal edema is seen in the periventricular brain by T2 hyperintensities on T2-weighted MRIs,32
and has been previously reported in humans.33 We observed periventricular T2 signal around the anterior and
lateral aspects of the lateral ventricles in most mice. T2
bright signal was associated with areas of lighter staining
and more diffuse tissue on the H&E images. Localization
of the periventricular signal to predominantly anterior
regions of the lateral ventricles has been previously reported,34 however it has not been well studied. The significance and relationship of this regional ependymal
specification to CSF circulation and fluid movement merits
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expression than the GEMM. While tumor could be seen
along the floor of the 4V and the underlying pontine brain
tissue in the human specimen (Supplementary Figure
8), human DIPG dissemination along the lateral ventricle
subependyma and within the lateral ventricles has not
been well described, and we were not able to obtain samples to characterize them.
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A primary limitation of this study is the method through
which the DF-1 cells were injected. Because the DF-1 cell injection is done by hand, DF-1 cells may have been injected
into the fourth ventricle. However, the tumor cells were observed throughout the ventricular system, subependyma,
and leptomeninges, suggesting that the tumor was able to
spread beyond its location in the fourth ventricle. Our study
examined only the Nestin-Tva GEMM of DIPG. Nestin expression is not limited to cells in the brainstem regions, unlike
Pax3. Previous studies have been able to generate gliomas
in the cerebral cortex parenchyma following virus injection
into the cerebral cortex in the Nestin-Tva DIPG rodent model
used in this present study, but not the Pax3-Tva model, due to
the different locations of cells that express these proteins.25
However, hydrocephalus was reported after intracerebral injection in Pax-3 GEMMs, suggesting that the leptomeningeal
disease and associated hydrocephalus is not just a consequence of this model’s use of Nestin-Tva expressing cells.
Furthermore, we can make several interpretations from
the intraventricular injection cohort data. First, the molecular characteristics of the tumors in the intraventricular
injection cohort differed from those in the intrapontine
injection cohort, as we observed significantly decreased
Olig2 expression and the absence of pseudopalisading necrosis. This indicates that the widespread subependymal
tumor dissemination observed in the pontine injections
were likely not due to contamination of the ventricular
system with DF-1 cells due to technical error.
Second, if the intraventricular and subependymal tumor
dissemination observed in the 100 000 pontine injection cohort was due to technical error involving a missed injection
of the tumor into the lateral ventricles (as opposed to the
pons), we would have likely seen similar rates of mortality as
we did in our 100 000 intraventricular injections. In contrast,
the 100 000 pontine injection cohort was kept alive for 3–4
weeks before sacrifice, and select litters were followed for
up to 5–6 weeks for serial imaging. Therefore, it is unlikely
that the 100 000 pontine injection cohort DF-1 cells were injected into the CSF spaces as a result of technical error.
Third, in the 50 000 DF-1 cell intraventricular cohorts,
not all animals with subependymal tumor had lateral
ventricle tumor, however all animals with lateral ventricle tumor had subependymal tumor. The lower rates of
subependymal and ventricle tumor development in the
intraventricular cohort suggest that direct injection of the
tumor through the CSF spaces is an unlikely mechanism
for the disease dissemination observed. Instead, these results suggest a general pattern: that intrapontine DF-1 cells
follow subependymal and leptomeningeal spread patterns, with growth in the lateral ventricle and third ventricle
subependymal zones that expands into the ventricles and
fragments. We did not observe evidence of heavy tumor
burden in the fourth ventricle subependyma nor fourth

Supplementary Material
Supplementary material is available at Neuro-Oncology
Advances online.

Keywords
cerebrospinal fluid | diffuse intrinsic pontine glioma | hydrocephalus | leptomeninges | subventricular zone.

Funding
National Institutes of Health [R01 EB027223 to H.C., R01EB030102
to H.C., R01 NS110793 to J.M.S.]. Prayers From Maria Foundation
to J.B.R.

Conflict of interest statement. The authors have no conflicts of
interest to declare that are relevant to the content of this article.

Authorship Statement. Conceptualization and methodology:
J.B.R., H.C., and J.M.S. Data curation: S.P., D.Y., Y.Y., L.Y., C.P.P.,
D.D., and P.E. Analysis and interpretation of data: S.P. and J.M.S.
Drafting and editing of the manuscript: S.P. and J.M.S. All authors have significantly contributed and seen and reviewed the
final manuscript.

References
1.

Tinkle CL, Orr BA, Lucas JT, et al. Rapid and fulminant leptomeningeal
spread following radiotherapy in diffuse intrinsic pontine glioma. Pediatr
Blood Cancer. 2017;64(8):e26416.

Downloaded from https://academic.oup.com/noa/article/4/1/vdac059/6574597 by Washington University in St. Louis user on 15 December 2022

Limitations

ventricle ependymal disruption, suggesting that the tumor
cells observed in the cerebral aqueduct and fourth ventricle
likely disseminated within the ventricular system following
outgrowth and fragmentation from the subependyma.
Serial MRI imaging was performed at 2 time points
post-DF-1 cell injection (3 and 5 weeks) and progressive tumor dissemination was identified (Supplementary
Figure 7). A longitudinal study including additional scans
at predetermined time points prior to 3 weeks postinjection
for each animal would allow more detailed evaluation of
tumor progression in this model. In addition, future studies
targeting the cellular and molecular mechanisms of CSF
and tumor movement across and within the ependyma are
needed in order to understand the leptomeningeal disease
and hydrocephalus in DIPG.

Neuro-Oncology
Advances

further investigation. There may be distinct molecular
characteristics of these ependymal regions that allow for
fluid movement across the ventricular surface. Finally, as
these anterior regions are adjacent to and overlapping the
SVZ, similar mechanisms may be responsible to both fluid
movement and subependymal tumor spread to this area.

11

12

Pan et al. Tumor dissemination in a murine model of DIPG

2.

3.

5.

6.

7.

8.
9.

10.
11.
12.

13.

14.

15.

16.

17. Willard N, Kleinschmidt-DeMasters BK. Massive dissemination of adult
glioblastomas. Clin Neuropathol. 2015;34(6):330–342.
18. Tamura M, Ohye C, Nakazato Y. Pathological anatomy of autopsy brain
with malignant glioma. Neurol Med Chir (Tokyo). 1993;33(2):77–80.
19. Caretti V, Bugiani M, Freret M, et al. Subventricular spread of diffuse
intrinsic pontine glioma. Acta Neuropathol. 2014;128(4):605–607.
20. Semple BD, Blomgren K, Gimlin K, Ferriero DM, Noble-Haeusslein LJ.
Brain development in rodents and humans: identifying benchmarks of
maturation and vulnerability to injury across species. Prog Neurobiol.
2013;106–107:1–16.
21. Castaneyra-Ruiz L, Morales DM, McAllister JP, et al. Blood exposure causes ventricular zone disruption and glial activation in vitro. J
Neuropathol Exp Neurol. 2018;77(9):803–813.
22. McAllister JP, Guerra MM, Ruiz LC, et al. Ventricular zone disruption in
human neonates with intraventricular hemorrhage. J Neuropathol Exp
Neurol. 2017;76(5):358–375.
23. Strahle J, Garton HJL, Maher CO, et al. Mechanisms of hydrocephalus
after neonatal and adult intraventricular hemorrhage. Transl Stroke Res.
2012;3(suppl 1):25–38.
24. Whiteside TL. The tumor microenvironment and its role in promoting
tumor growth. Oncogene. 2008;27(45):5804–5812.
25. Lee JH, Lee JE, Kahng JY, et al. Human glioblastoma arises from
subventricular zone cells with low-level driver mutations. Nature.
2018;560(7717):243–247.
26. Misuraca KL, Hu G, Barton KL, Chung A, Becher OJ. A novel mouse
model of diffuse intrinsic pontine glioma initiated in Pax3-expressing
cells. Neoplasia. 2016;18(1):60–70.
27. Hladky SB, Barrand MA. Mechanisms of fluid movement into, through
and out of the brain: evaluation of the evidence. Fluids Barriers CNS.
2014;11(1):26.
28. Iliff JJ, Wang M, Liao Y, et al. A paravascular pathway facilitates CSF
flow through the brain parenchyma and the clearance of interstitial solutes, including amyloid β. Sci Transl Med. 2012;4(147):147ra111.
29. Louveau A, Smirnov I, Keyes TJ, et al. Structural and functional
features of central nervous system lymphatic vessels. Nature.
2015;523(7560):337–341.
30. Aspelund A, Antila S, Proulx ST, et al. A dural lymphatic vascular system
that drains brain interstitial fluid and macromolecules. J Exp Med.
2015;212(7):991–999.
31. Casaca-Carreira J, Temel Y, Hescham SA, Jahanshahi A. Transependymal
cerebrospinal fluid flow: opportunity for drug delivery? Mol Neurobiol.
2018;55(4):2780–2788.
32. Wardlaw JM, Valdés Hernández MC, Muñoz-Maniega S. What are
white matter hyperintensities made of? Relevance to vascular cognitive
impairment. J Am Heart Assoc. 2015;4(6):001140.
33. Isaacs AM, Smyser CD, Lean RE, et al. MR diffusion changes in the
perimeter of the lateral ventricles demonstrate periventricular injury
in post-hemorrhagic hydrocephalus of prematurity. Neuroimage Clin.
2019;(24):102031.
34. Todd KL, Brighton T, Norton ES, et al. Ventricular and periventricular
anomalies in the aging and cognitively impaired brain. Front Aging
Neurosci. 2018;(9):445.

Downloaded from https://academic.oup.com/noa/article/4/1/vdac059/6574597 by Washington University in St. Louis user on 15 December 2022

4.

Wagner S, Benesch M, Berthold F, et al. Secondary dissemination in
children with high-grade malignant gliomas and diffuse intrinsic pontine
gliomas. Br J Cancer. 2006;95(8):991–997.
Gururangan S, McLaughlin CA, Brashears J, et al. Incidence and patterns of neuraxis metastases in children with diffuse pontine glioma. J
Neurooncol. 2006;77(2):207–212.
Nikbakht H, Panditharatna E, Mikael LG, et al. Spatial and temporal homogeneity of driver mutations in diffuse intrinsic pontine glioma. Nat
Commun. 2016;(7):11185.
Hoffman LM, van Zanten SEMV, Colditz N, et al. Clinical, radiologic,
pathologic, and molecular characteristics of long-term survivors of
Diffuse Intrinsic Pontine Glioma (DIPG): a collaborative report from the
International and European Society for Pediatric Oncology DIPG registries. J Clin Oncol. 2018;36(19):1963–1972.
Giussani C, Guida L, Biassoni V, et al. Retrospective analysis of the
clinical and radiological features of 94 consecutive DIPGs patients to
investigate the factors determining the development of hydrocephalus and its impact on clinical status and survival. Childs Nerv Syst.
2020;36(11):2701–2705.
Lamba N, Fick T, Nandoe Tewarie R, Broekman ML. Management of hydrocephalus in patients with leptomeningeal metastases: an ethical approach to decision-making. J Neurooncol. 2018;140(1):5–13.
Warren KE. Diffuse intrinsic pontine glioma: poised for progress. Front
Oncol. 2012;(2):205.
Qin EY, Cooper DD, Abbott KL, et al. Neural precursor-derived
pleiotrophin mediates subventricular zone invasion by glioma. Cell.
2017;170(5):845–859.e19.
Misuraca KL, Cordero FJ, Becher OJ. Pre-clinical models of diffuse intrinsic pontine glioma. Front Oncol. 2015;(5):172.
Lapin DH, Tsoli M, Ziegler DS. Genomic insights into diffuse intrinsic
pontine glioma. Front Oncol. 2017;(7):57.
Yushkevich PA, Gao Y, Gerig G. ITK-SNAP: an interactive tool for
semi-automatic segmentation of multi-modality biomedical images.
In: Proceedings of the Annual International Conference of the IEEE
Engineering in Medicine and Biology Society, EMBS, October. Vol 2016.
2016:3342–3345.
Lieberman NAP, Degolier K, Kovar HM, et al. Characterization of
the immune microenvironment of diffuse intrinsic pontine glioma:
implications for development of immunotherapy. Neuro Oncol.
2019;21(1):83–94.
Buczkowicz P, Bartels U, Bouffet E, Becher O, Hawkins C.
Histopathological spectrum of paediatric diffuse intrinsic pontine
glioma: diagnostic and therapeutic implications. Acta Neuropathol.
2014;128(4):573–581.
Jiménez AJ, Domínguez-Pinos MD, Guerra MM, Fernández-Llebrez P,
Pérez-Fígares JM. Structure and function of the ependymal barrier
and diseases associated with ependyma disruption. Tissue Barriers.
2014;2(1):e28426.
Iacoangeli M, di Rienzo A, Colasanti R, et al. Endoscopy-verified occult subependymal dissemination of glioblastoma and brain metastasis undetected by MRI: prognostic significance. Onco Targets Ther.
2012;5:449–56.

